Latest News
Zoetis Acquires Ethos Diagnostic Science to Expand Diagnostics Capabilities in Veterinary Services
Tuesday 11 February 2020

11 February 2020 - US animal health company Zoetis Inc. (NYSE: ZTS) has acquired Ethos Diagnostic Science, a veterinary reference lab business to enhance diagnostics capabilities for all veterinary species, the company said.
Terms of the transaction were not disclosed.
Having entered the veterinary reference laboratory space through the acquisitions of both Phoenix Lab and ZNLabs in 2019, Zoetis continues to grow its diagnostics presence to offer comprehensive and enhanced value to veterinarians in the US Financial terms of the transaction are not being disclosed.
Ethos Diagnostic Science is a business unit of Ethos Veterinary Health and has laboratory locations in Boston, Denver and San Diego.
Its clinical team has decades of combined experience in veterinary and laboratory medicine and is proud of the strong client relationships built through comprehensive review of accurate, reliable results for the best possible patient outcomes.
Ethos Diagnostic Science performs testing for all veterinary species in hematology, clinical chemistry, urinalysis, microbiology, parasitology, endocrinology, serology, cytology and histology.
It aims to provide the highest quality results in rapid turnaround times, while advancing the field of veterinary diagnostic medicine.
Zoetis discovers, develops, manufactures and commercialises medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries.
Ethos Diagnostic Science, part of Ethos Veterinary Health, is a full-service veterinary diagnostic laboratory founded in 2015 as the former STAT Veterinary Lab.
Date Published: 11/02/2020
Target: Ethos Diagnostic Science
Country: USA
Sector: Healthcare
Type: Corporate acquisition
Status: Closed
Buyer: Zoetis Inc
Terms of the deal were not disclosed